-

BayCare Breaks Ground on Cancer Institute Expansion to Bring Revolutionary MEVION S250-FIT Proton Therapy to Tampa

TAMPA--(BUSINESS WIRE)--BayCare, a leading not-for-profit health care system, announces the groundbreaking of a $33 million expansion to the BayCare Cancer Institute at St. Joseph's Hospital that will house the revolutionary MEVION S250-FIT Proton Therapy System*. BayCare will be the first to offer this advanced therapy in Tampa, Florida, with the facility expected to be operational by the end of 2025.

Proton therapy is an advanced form of radiation therapy that uses protons—positively charged particles—instead of X-rays to precisely target tumors. This precision allows for higher doses of radiation to be delivered to the cancer cells while minimizing exposure to surrounding healthy tissue and organs, potentially reducing side effects and improving patient outcomes.

The MEVION S250-FIT is the first and only proton therapy system installed in a space like conventional radiation therapy machines, making it more accessible and cost-effective for hospitals and cancer centers. Proton therapy is a highly precise form of radiation therapy that targets tumors with greater accuracy, minimizing damage to surrounding healthy tissue and organs. This is particularly important for cancers located near critical structures, such as the brain, spine, and heart.

“We are the best place to work, practice and receive care, enabling us to continue to fulfill our vision and our mission," said Stephanie Conners, President and CEO of BayCare. "Innovative technologies like proton therapy are why we continue to be the No. 1 health system and provider of choice in the Tampa Bay region."

"We are thrilled to partner with BayCare to bring the MEVION S250-FIT to Tampa," said Tina Yu, CEO of Mevion Medical Systems. "This innovative system will make proton therapy more accessible to patients in the region, and we are confident that it will have a significant impact on the lives of those battling cancer."

The expansion of the BayCare Cancer Institute at St. Joseph’s Hospital is expected to be completed by the end of 2025.

About Mevion Medical Systems

Mevion Medical Systems is the leading provider of compact proton therapy systems for cancer care. Dedicated to advancing the design and accessibility of proton therapy worldwide, Mevion pioneered the single-room platform and continues to further the science and application of proton therapy. Since 2013, Mevion compact proton therapy single-room systems have been used by leading cancer centers for treating patients. Mevion's series of products, including the flagship MEVION S250i and MEVION S250-FIT with HYPERSCAN pencil beam scanning, represent the world's most compact proton therapy systems that eliminate the obstacles of size, complexity, and cost. Mevion is headquartered in Littleton, Massachusetts with a presence in Europe and Asia. For more information, please visit www.mevion.com.

*The MEVION S250-FIT Proton Therapy System is not yet available for clinical use.

Contacts

Media Contact:
Jacqueline Abner-Pongratz
Mevion Medical Systems
Jacqueline.Pongratz@mevion.com

Mevion Medical Systems


Release Versions

Contacts

Media Contact:
Jacqueline Abner-Pongratz
Mevion Medical Systems
Jacqueline.Pongratz@mevion.com

Social Media Profiles
More News From Mevion Medical Systems

Rönesans Selects MEVION S250-FIT for Landmark Proton Therapy Investment in Türkiye

LITTLETON, Mass. & ISTANBUL--(BUSINESS WIRE)--Mevion Medical Systems today announced that Rönesans Holding has selected and purchased the MEVION S250-FIT Proton Therapy System™ as part of a major investment in advanced cancer care at Çam ve Sakura City Hospital in Istanbul. The planned installation will bring together Rönesans Sağlık Yatırım- Rönesans Healthcare Investment, Mevion Medical Systems and Meditel Healthcare to introduce a new model for proton therapy in Türkiye. The system will be p...

Auburn Installs Superconducting Proton Accelerator for Nation’s Only University-Led Space Electronics Testing Facility of Its Kind

HUNTSVILLE, Ala.--(BUSINESS WIRE)--Today, Auburn University’s Applied Research Institute (AUARI) announced the installation of its new superconducting 200 MeV proton accelerator, an important step in opening the nation’s first university-led proton testing facility dedicated to qualifying space electronics. The RAD-FX-200 superconducting synchrocyclotron, manufactured and installed by Mevion Medical Systems, is the centerpiece of AUARI’s new Radiation Hardening Facility, created to address the...

Mevion Announces First Clinical Treatment on the MEVION S250-FIT™ Proton Therapy System

LITTLETON, Mass.--(BUSINESS WIRE)--Mevion Medical Systems, a global leader in compact proton therapy, today announced that the world’s first clinical proton therapy treatment delivered inside an existing conventional radiation therapy vault has been completed at Stanford Medicine Cancer Center. The treatment was delivered on the MEVION S250-FIT Proton Therapy System™. The milestone establishes a new category of proton therapy delivery: a compact single-room system that fits within existing radi...
Back to Newsroom